On March 22nd, the FDA announced its approval of the TOBI Podhaler (tobramycin inhalation powder) for the management of cystic fibrosis patients with Pseudomonas aeruginosa.
The TOBI Podhaler is a plastic, handheld inhaler device containing a dry powder formulation of tobramycin. The Podhaler can simplify treatment because:
- TOBI Podhaler is portable and requires no nebulizer, refrigeration or power source to deliver the medicine
- TOBI Podhaler shortens treatment time by about 70% compared to nebulized TOBI®
For the complete FDA press release, click here.
People living with CF (or their care givers) who are interested in this treatment option should consult with their doctor and/or CF Clinic staff.